Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | STS | P08842 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | CCR1 | P32246 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20601236 | 0.99 | KDM4E (0.50) | KDM4EPKMKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL20601221 | 0.96 | KDM4E (0.53) | KDM4EPKMKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL20601223 | 0.96 | KDM4E (0.53) | KDM4EPKMKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL20601293 | 0.90 | KDM4E (0.51) | KDM4EPKMKMT2AHTTNPSR1 | |
| SCHEMBL20601226 | 0.89 | KDM4E (0.50) | KDM4EPKMKMT2AHTTALDH1A1 | |
| SCHEMBL20601431 | 0.89 | KDM4E (0.50) | KDM4EPKMKMT2AMEN1GPR119 | |
| SCHEMBL20601257 | 0.86 | KDM4E (0.53) | KDM4EPKMKMT2AHTTALDH1A1 | |
| SCHEMBL20601259 | 0.86 | KDM4E (0.53) | KDM4EPKMKMT2AHTTALDH1A1 | |
| SCHEMBL20615730 | 0.85 | SMN1; SMN2 (0.51) | KDM4EPKMKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL20600961 | 0.85 | SMN1; SMN2 (0.51) | KDM4EPKMKMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210078988-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-03-18 | — | — | US | disclosed |
| US-20210078988-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-03-18 | — | — | US | disclosed |
| EP-3645519-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-05-06 | — | — | EP | disclosed |
| CN-110770222-A | Modulators of indoleamine2, 3-dioxygenase | 葛兰素史克知识产权开发有限公司 | 2020-02-07 | — | — | CN | disclosed |
| WO-2019003142-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-03 | — | — | WO | disclosed |
| WO-2019003142-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078988-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, TPH1 | KDM4E 657/4885PKM 892/4885KMT2A 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.